Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506463 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 397
- Enrollment target
NCT04506463 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 397 participants.
The verdict
NCT04506463, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 397 participants
- Enrollment target
Study Summary
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
Interventions
- DRUG Placebo
- DRUG MM-II dose I
- DRUG MM-II dose II
- DRUG MM-II dose III
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04506463
The ClinicalTrials.gov registry entry for NCT04506463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04506463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04506463 about?
NCT04506463 is a clinical study titled "Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis". This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
What is the current status of trial NCT04506463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 397 participants. The study started on 2020-12-22. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT04506463?
The interventions under investigation include: Placebo (DRUG), MM-II dose I (DRUG), MM-II dose II (DRUG), MM-II dose III (DRUG).
Who is sponsoring clinical trial NCT04506463?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.